Open AccessHedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF‐A expression in hepatocellular carcinoma
Author(s) -
Pinter Matthias,
Sieghart Wolfgang,
Schmid Monika,
Dauser Bernhard,
Prager Gerald,
Dienes Hans Peter,
Trauner Michael,
PeckRadosavljevic Markus
Publication year - 2013
Publication title -
ueg journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 35
eISSN - 2050-6414
pISSN - 2050-6406
DOI - 10.1177/2050640613496605
Subject(s) - hepatocellular carcinoma , medicine , downregulation and upregulation , angiogenesis , cancer research , vegf receptors , hedgehog , hedgehog signaling pathway , vascular endothelial growth factor , oncology , signal transduction , gene , microbiology and biotechnology , biology , biochemistry
Background Dysregulation and activation of Hedgehog (Hh) signalling may contribute to tumorigenesis, angiogenesis, and metastatic seeding in several solid tumours. Objective We investigated the impact of Hh inhibition on tumour growth and angiogenesis using in‐vitro and in‐vivo models of hepatocellular carcinoma (HCC). Methods The effect of the Hh pathway inhibitor GDC‐0449 on tumour growth was investigated using an orthotopic rat model. Effects on angiogenesis were determined by immunohistochemical staining of von Willebrand factor antigen and by assessing the mRNA expression of several angiogenic factors. In vitro, HCC cell lines were treated with GDC‐0449 and evaluated for viability and expression of vascular endothelial growth factor (VEGF). Endothelial cells were evaluated for viability, migration, and tube formation. Results In the orthotopic HCC model, GDC‐0449 significantly decreased tumoral VEGF expression which was accompanied by a significant reduction of microvessel density and tumour growth. In HCC cells, GDC‐0449 had no effect on cell growth but significantly reduced target gene regulation and VEGF expression while having no direct effect on endothelial cell viability, migration, and tube formation. Conclusions Hh inhibition with GDC‐0449 downregulates tumoral VEGF production in vitro and reduces tumoral VEGF expression, angiogenesis, and tumour growth in an orthotopic HCC model.